Page last updated: 2024-11-02

pindolol and Cachexia

pindolol has been researched along with Cachexia in 1 studies

Pindolol: A moderately lipophilic beta blocker (ADRENERGIC BETA-ANTAGONISTS). It is non-cardioselective and has intrinsic sympathomimetic actions, but little membrane-stabilizing activity. (From Martindale, The Extra Pharmocopoeia, 30th ed, p638)
pindolol : A member of the class of indols which is the 2-hydroxy-3-(isopropylamino)propyl ether derivative of 1H-indol-4-ol.

Cachexia: General ill health, malnutrition, and weight loss, usually associated with chronic disease.

Research Excerpts

ExcerptRelevanceReference
"In the Yoshida AH130 hepatoma rat cancer cachexia model and compared with placebo, 50 mg/kg/d S-oxprenolol (HR: 0."8.31The atypical β-blocker S-oxprenolol reduces cachexia and improves survival in a rat cancer cachexia model. ( Álvarez Ladrón, N; Alves de Lima Junior, E; Anker, MS; Anker, SD; Argiles, JM; Busquets, S; Coats, AJS; Jové, Q; López-Soriano, FJ; Millman, O; Oosterlee, A; Palus, S; Springer, J; Szymczyk, A; von Haehling, S; Yuan, L, 2023)
"In the Yoshida AH130 hepatoma rat cancer cachexia model and compared with placebo, 50 mg/kg/d S-oxprenolol (HR: 0."4.31The atypical β-blocker S-oxprenolol reduces cachexia and improves survival in a rat cancer cachexia model. ( Álvarez Ladrón, N; Alves de Lima Junior, E; Anker, MS; Anker, SD; Argiles, JM; Busquets, S; Coats, AJS; Jové, Q; López-Soriano, FJ; Millman, O; Oosterlee, A; Palus, S; Springer, J; Szymczyk, A; von Haehling, S; Yuan, L, 2023)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Yuan, L1
Springer, J1
Palus, S1
Busquets, S1
Jové, Q1
Alves de Lima Junior, E1
Anker, MS1
von Haehling, S1
Álvarez Ladrón, N1
Millman, O1
Oosterlee, A1
Szymczyk, A1
López-Soriano, FJ1
Anker, SD1
Coats, AJS1
Argiles, JM1

Other Studies

1 other study available for pindolol and Cachexia

ArticleYear
The atypical β-blocker S-oxprenolol reduces cachexia and improves survival in a rat cancer cachexia model.
    Journal of cachexia, sarcopenia and muscle, 2023, Volume: 14, Issue:1

    Topics: Adrenergic beta-Antagonists; Animals; Cachexia; Humans; Liver Neoplasms; Mice; Oxprenolol; Pindolol;

2023